Neurofilament as a potential biomarker for spinal muscular atrophy-Reference-Cited by-同舟云学术

Neurofilament as a potential biomarker for spinal muscular atrophy

Published:2019-04-17 Issue:5 Volume:6 Page:932-944
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Darras Basil T.¹,Crawford Thomas O.²³,Finkel Richard S.⁴,Mercuri Eugenio⁵,De Vivo Darryl C.⁶,Oskoui Maryam⁷,Tizzano Eduardo F.⁸,Ryan Monique M.⁹,Muntoni Francesco¹⁰¹¹,Zhao Guolin¹²,Staropoli John¹²,McCampbell Alexander¹²,Petrillo Marco¹²,Stebbins Christopher¹²,Fradette Stephanie¹²,Farwell Wildon¹²,Sumner Charlotte J.²¹³

Affiliation:

1. Department of Neurology Boston Children's Hospital and Harvard Medical School Boston Massachusetts

2. Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland

3. Department of Pediatrics Johns Hopkins University School of Medicine Baltimore Maryland

4. Division of Neurology Department of Pediatrics Nemours Children's Hospital Orlando Florida

5. Department of Paediatric Neurology Catholic University Rome Italy

6. Departments of Neurology and Pediatrics Columbia University Irving Medical Center New York New York

7. Department of Neurology and Neurosurgery and Department of Pediatrics McGill University Montreal Quebec Canada

8. Department of Clinical and Molecular Genetics and Rare Diseases Unit Hospital Vall d′Hebron and Centro de Investigacíon Biomédica en Red Enfermedades Raras (CIBERER) Barcelona Spain

9. Royal Children's Hospital Murdoch Children's Research Institute and University of Melbourne Melbourne Australia

10. Dubowitz Neuromuscular Centre University College London London United Kingdom

11. NIHR Great Ormond Street Hospital Biomedical Research Centre London United Kingdom

12. Biogen Cambridge Massachusetts

13. Department of Neuroscience Johns Hopkins University School of Medicine Baltimore Maryland

Funder

Biogen

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.779

Reference43 articles.

1. Spinal Muscular Atrophies

2. Spinraza 12 mg solution for injection [summary of product characteristics].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004312/WC500229704.pdf. Accessed June 4 2018.

3. Spinraza [package insert]. Cambridge MA: Biogen 2018.

4. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

5. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and opportunities in spinal muscular atrophy therapeutics;The Lancet Neurology;2024-02

2. Neuromuscular disorders in the omics era;Clinica Chimica Acta;2024-01

3. Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice;Annals of Neurology;2023-12-28

4. Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi;Frontiers in Neurology;2023-12-13

5. Spinal Muscular Atrophy Types, Innovations in Diagnosis and Treatment;Journal of Dr Behcet Uz Children s Hospital;2023-12-04